ANA Highlights: Emerging Issues in Neurogenetics

The course is an overview of genetic testing research, variants of uncertain significance, role of somatic mosaicism in neurological diseases, the role of big data in tackling brain disorders of children and adults, pharmacogenomics and importance of genetic diversity in research toward clinical utility in neurology. Dr. M. Elizabeth Ross, Nathan Cummings Professor and Head, Laboratory of Neurogenetics and Development, Director, Center for Neurogenetics at Weill Cornell Medicine is the lead for this module.

This course is Chapter 2 of the larger ANA Highlights Neurogenetics series available for ABPN self assessment credit. We have separated the larger course into these smaller chapters for those not interested in the full course.

The ANA Highlights Neurogenetics program is chaired by Dr. M. Elizabeth Ross, Nathan Cummings Professor and Head, Laboratory of Neurogenetics and Development, Director, Center for Neurogenetics at Weill Cornell Medicine. The ANA Highlights bite-size learning program is chaired by Michelle C. Johansen, MD, PhD, Assistant Professor of Neurology, Cerebrovascular Division at the Johns Hopkins Hospital. 

The ANA received a grant from Illumina in support of this activity.

Following this activity, the ANA expects learners to be more confident in their ability to:

  • Understand the different types of neurogenetic testing available today, and prospects for future developments
  • Recognize the legal and ethical issues involved with neurogenetic testing
  • Improve patient care through the above-listed capabilities
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
    The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Neurological Association designates this Enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Participation
Activity opens: 
03/22/2023
Activity expires: 
03/22/2026
Rating: 
0

The planners and faculty for this activity do not have any relationships to disclose unless listed below. All relevant relationships with ACCME-defined ineligible companies were mitigated according to ACCME Standards prior to the start of the activity.

Gemma Carvill: Research grant with Stoke Therapeutics    
Derek Narendra: Spark Therapeutics. I anticipate that my lab may receive research funding as part of a research collaboration prior to my presentation, but has not received this funding yet.    
Daniel Geschwind: Biogen-honoraria for consulting, F.Hoffman-La Roche Ltd.-funding 

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
    The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Neurological Association designates this Enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Participation
Please login or register to take this activity.